-
Senomyx Gets U.S. Patent Covering Composition-Use of Novel (SNMX)
Wednesday, May 11, 2011 - 8:40am | 163Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that the Company has been granted U.S. Patent No. 7,939,671, which includes...
-
Benzinga's Top Pre-Market NASDAQ Gainers (ROVI, ASYS, ZAGG, HALO)
Wednesday, May 11, 2011 - 8:19am | 138Rovi Corporation (NASDAQ: ROVI) shares surged 13.12% to $56.20 in the pre-market session. ROVI reported upbeat Q1 earnings. Amtech Systems Inc (NASDAQ: ASYS) shares advanced 7.09% to $22.67 in the pre-market session. ASYS reported its Q2 net income at $7.5 million, versus a net income of $5.0...
-
Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
Wednesday, May 11, 2011 - 8:08am | 157Quest Diagnostics Incorporated (NYSE: DGX) and Spark Acquisition Corporation, its wholly owned subsidiary, announced today the completion of the final extension of the subsequent offering period with respect to Spark's cash tender offer for all outstanding shares of common stock of Celera...
-
Jefferies & Company Reports on Infinity Pharmaceuticals (INFI)
Wednesday, May 11, 2011 - 8:05am | 127In a report released earlier today, Jefferies & Company commented on Infinity Pharmaceuticals (NASDAQ: INFI). In the report, Jefferies was positive. Jefferies writes, “[INFI] reported a narrower 1Q11 loss on higher revenues; cash of $91M at end-1Q11, $200M-$205M committed R&D funding in...
-
Celsion Corporation Regains Compliance With NASDAQ Listing Requirements (CLSN)
Wednesday, May 11, 2011 - 8:03am | 137Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it has received notification from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum Market Value of Listed Securities requirement for continued listing...
-
Oppenheimer Adjusts BPAX Estimates
Wednesday, May 11, 2011 - 7:51am | 66Oppenheimer is making some adjustments to its estimates on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) “We note BPAX's cash balance of ~$51M, which we believe is sufficient to fund operations into 2012,” Oppenheimer writes. “We adjust our 2011 EPS estimate to ($0.69) from ($0.43) and our 2012...
-
J.P. Morgan Reports on Allos Therapeutics (ALTH)
Wednesday, May 11, 2011 - 7:45am | 157In a report released yesterday, J.P. Morgan commented on Allos Therapeutics (NASDAQ: ALTH). In the report, J.P. Morgan was very positive on the company. J.P. Morgan writes, “Allos' 1Q results had a number of moving parts, some were positive and some were negative. On the positive side, Allos...
-
Citi Reduces Price Target On Allos Therapeutics
Wednesday, May 11, 2011 - 7:35am | 111According to Citi, Allos Therapeutics (NASDAQ: ALTH) price target is reduced to $5. Citi said that it is reducing the PT to $5 based on the lower FY2011 FOLOTYN sales guidance of $48M - $55M comparing to previous CIRA and cons estimates of $57M and $63M. “Our new growth estimates are more modest,...
-
Oncolytics Biotech Inc. Enters into Commercial Supply Agreement with SAFC
Wednesday, May 11, 2011 - 7:34am | 70Oncolytics Biotech Inc. (NASDAQ: ONCY) today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus. Under the terms of the agreement, SAFC will perform...
-
Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze
Wednesday, May 11, 2011 - 7:29am | 148Halozyme Therapeutics, Inc. (Nasdaq: HALO) and ViroPharma Incorporated (Nasdaq: VPHM), today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze. Under terms of the agreement, Halozyme may receive...
-
Oppenheimer Raises EPS Estimate From $0.58 To $0.69 On ARNA
Wednesday, May 11, 2011 - 7:27am | 84In a recent report, Oppenheimer has raised the EPS estimate on Arena Pharmaceuticals (NASDAQ: ARNA) from $0.58 to $0.69 and continues to see obstacles for the Lorcasserin approval. In the report, Oppenheimer said, "ARNA plans to conduct 3 mo. preclinical trials to resolve this key issue, notably...
-
JP Morgan Lowers PT On Allos Therapeutics To $8
Wednesday, May 11, 2011 - 6:50am | 27JP Morgan has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $10 to $8 and maintains its Overweight rating.
-
Citigroup Lowers PT On Allos Therapeutics To $5
Wednesday, May 11, 2011 - 6:32am | 26Citigroup has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $7 to $5 and maintains its Buy rating.
-
Earnings Scheduled For May 11 (TM, MT, TEVA, ZIP, M, BAM, CSCO, IAG, SYMC, ACXM, SSRX, SVN, APAC, CONM)
Wednesday, May 11, 2011 - 2:20am | 375Toyota Motor Corp (NYSE: TM) is estimated to post its FQ3 EPS at $0.64 on revenue of $63.42 billion. Arcelor Mittal (NYSE: MT) is expected to post its Q1 earnings at $0.48 per share on revenue of $22.03 billion. Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is projected to post its Q1...
-
Short-Term Action Broke Through Resistance 05-10-2011
Tuesday, May 10, 2011 - 7:21pm | 897Cusick's Corner The mood in the market is more upbeat. Short-term market action broke through resistance of 1350 on the June S&P500 future which means that this move to the upside might have a fighting chance. Small Cap and Mid Cap stocks have been leading this market's move higher. Most...